Update on CAR-T Therapies in Acute and Chroni...

In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed ov ...  Show more

In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have h ...  Show more

How can you optimize the treatment pathway for relapsed or refractory chronic lymphocytic leukemia (CLL)? Join the experts as they delve into the latest updates from EHA 2024.
  
Credit available for this activity expires: 07/31/25
Earn Credit / Learning Obje ...

Join the experts for an in-depth discussion on the latest developments in targeted therapies for relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and a look ahead to the upcoming EHA2024 conference. Credit available for this activity expires: 6/6/2025 Earn Credit / Lea ...  Show more

Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provid ...  Show more

Send us Fan MailAs a result of the rapid adoption CAR-T therapy for certain lymphoid malignancies and multiple myeloma, of these treatments, CRS and ICANS will become more common in IM wards in the coming years. Take a listen to learn about how to treat this emerging condition. T ...  Show more